The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The recent advent of a highly efficacious class of low-density lipoprotein cholesterol (LDL-C) lowering agents, the proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors, has transformed dyslipidaemia management in patients with cardiovascular disease as well as those with familial hypercholesterolemia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Curr. Opin. Cardiol.

Title: Current opinion in cardiology

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1531-7080

ISSN (Print): 0268-4705

Publication date (Electronic): Sep 2017

Volume: 32

Issue: 5

Affiliations

[1 ] aCambridge Cardiac Care Centre, Cambridge bDepartment of Medicine, McMaster University, Hamilton cLMC Diabetes & Endocrinology, Brampton dLeadership Sinai Centre for Diabetes, Mount Sinai Hospital eDepartment of Internal Medicine, University of Toronto, Toronto fUniversity of Western Ontario, London, Ontario, Canada gCenter for Healthcare Delivery Sciences, Brigham and Women's Hospital, Harvard University Medical School, Boston, Massachusetts, USA hDivision of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital iDepartments of Surgery, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

Article

DOI: 10.1097/HCO.0000000000000424

PubMed ID: 28557865

SO-VID: 5ae26952-1c18-4e69-8631-c70c5bc4cc56

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by